HCV Treatment
HIV Glasgow: Generic Hepatitis C Drugs Purchased Online Produce High Cure Rates
- Details
- Category: HCV Treatment
- Published on Saturday, 29 October 2016 00:00
- Written by Keith Alcorn
Use of generic versions of direct-acting antivirals for hepatitis C resulted in very high cure rates for people who obtained the products through 3 buyers’ clubs, indicating that the generic products are effective, according to a set of poster presentations at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow) last week. People who purchased generic drugs were cured at a cost of around US$700-$900 in Southeast Asia and Eastern Europe, Andrew Hill of St. Stephen’s AIDS Trust reported.
Over 1 Million People Have Been Treated with New Hepatitis Drugs, But Cost Remains a Barrier
- Details
- Category: HCV Treatment
- Published on Friday, 28 October 2016 00:00
- Written by WHO
More than 1 million people have now received hepatitis C treatment using the new highly effective and well-tolerated direct-acting antiviral agents despite their high cost, according to a report released this week by the World Health Organization. The Global Report on Access to Hepatitis C Treatment: Focus on Overcoming Barriers is available online.
Response-Guided DAA Triple Regimen May Cure Hepatitis C in as Little as 3 Weeks
- Details
- Category: Approved HCV Drugs
- Published on Monday, 24 October 2016 00:00
- Written by Liz Highleyman
Response-guided therapy using 3 direct-acting antivirals without ribavirin cured a majority of easier-to-treat genotype 1b hepatitis C patients in just 3 weeks, according to results from a small pilot study published in the October 2016 edition of The Lancet Gastroenterology & Hepatology.
New Triple Combo Cures Most DAA-Experienced and Hard-to-Treat Hepatitis C Patients Without Ribavirin
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 24 October 2016 00:00
- Written by HIVandHepatitis.com
An investigational 3-drug coformulation from Gilead Sciences produced sustained virological response (SVR) in 95% to 97% of hard-to-treat hepatitis C patients in the Phase 3 POLARIS trials, including people who were previously treated with direct-acting antivirals and those with hepatitis C virus (HCV) genotype 3 and compensated cirrhosis, according to a recent company announcement. Gilead plans to request Food and Drug Administration approval of the new combination by the end of the year.
Resources for People with HIV and Hepatitis in Disaster Areas
- Details
- Category: HIV Treatment
- Published on Wednesday, 05 October 2016 00:00
- Written by HIVandHepatitis.com
During and after disasters such as Hurricane Matthew, people with medical conditions including HIV and viral hepatitis will be among those displaced and requiring emergency care. Government agencies offer resources for people with these and other chronic conditions, healthcare providers, and others who provide emergency and disaster-related services.
More Articles...
- EASL Paris: AbbVie 3D Regimen for 8 Weeks Cures Almost All HCV Genotype 1b Patients
- EASL Paris: 100% Cure Rate with AL-335, Odalasvir, and Simeprevir for 6 or 8 Weeks
- EASL Issues New Hepatitis C Treatment Recommendations For All Genotypes
- INHSU 2016: Risk of Reinfection Is a Concern After Successful Hepatitis C Treatment
Web Design and Development by